Immuron Takes PROIBS to America, as New U.S. Growth Engine Could be Taking Shape
Immuron (NASDAQ:IMRN) is adding another potentially important piece to its U.S. commercial strategy, announcing an exclusive distribution agreement with Sweden’s Calmino group AB to bring PROIBS to the American market. The move expands Immuron’s digestive-health portfolio beyond Travelan and gives the company another commercial product aimed at a large and recurring consumer-health need: the symptoms associated with irritable bowel syndrome. Importantly, this is not a molecule sitting years away from commercialization. PROIBS has already been sold in Sweden for more than a decade and, according to Calmino, was the best-selling IBS product in Swedish pharmacies during 2025, based on IQVIA sales data.